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Abstract
Development of a small animal model to study HIV replication and pathogenesis has been hampered by the failure of the
virus to replicate in non-primate cells. Most studies aimed at achieving replication in murine cells have been limited to
fibroblast cell lines, but generating an appropriate model requires overcoming blocks to viral replication in primary T
cells. We have studied HIV-1 replication in CD4
+ T cells from human CD4/ CCR5/Cyclin T1 transgenic mice. Expression of
hCD4 and hCCR5 in mouse CD4
+ T cells enabled efficient entry of R5 strain HIV-1. In mouse T cells, HIV-1 underwent reverse
transcription and nuclear import as efficiently as in human T cells. In contrast, chromosomal integration of HIV-1 proviral
DNA was inefficient in activated mouse T cells. This process was greatly enhanced by providing a secondary T cell receptor
(TCR) signal after HIV-1 infection, especially between 12 to 24 h post infection. This effect was specific for primary mouse T
cells. The pathways involved in HIV replication appear to be PKCh2, CARMA1-, and WASp-independent. Treatment with
Cyclosporin A (CsA) further relieved the pre-integration block. However, transcription of HIV-1 RNA was still reduced in
mouse CD4
+ T cells despite expression of the hCyclin T1 transgene. Additional post-transcriptional defects were observed at
the levels of Gag expression, Gag processing, Gag release and virus infectivity. Together, these post-integration defects
resulted in a dramatically reduced yield of infectious virus (300–500 fold) after a single cycle of HIV-1 replication. This study
implies the existence of host factors, in addition to those already identified, that are critical for HIV-1 replication in mouse
cells. This study also highlights the differences between primary T cells and cell lines regarding pre-integration steps in the
HIV-1 replication cycle.
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Introduction
A small animal model for HIV infection and pathogenesis
would be invaluable for basic research as well as for vaccine
development. Humanized mice can be used for this purpose. The
xenotransplant models include severe combined immunodeficien-
cy (SCID) mice transplanted with human fetal thymus or liver cells
(SCID-Hu (Thy/Liv)), SCID mice transplanted with human
peripheral blood lymphocytes (Hu-PBL-SCID) and Rag
2/2cc
2/2
mice reconstituted with human CD34
+ stem cells [1,2]. Although
these mice have been useful for in vivo HIV-1 pathogenesis studies,
as they have aspects of the human immune system, each model has
its limitations. B cells fail to develop in SCID-Hu (Thy/Liv) mice,
and in CD34
+ stem cell reconstituted mice, abnormal interactions
between human TCR and mouse MHC lead to defects in T cell
development [1], which represents a serious problem for most of
the xenotransplant models.
Various cell types in the immune system contribute to the
initiation, progression and prevention of HIV-1 induced disease.
Dendritic cells (DCs) and macrophages, for example, are required
for the initiation of adaptive immunity, but potentially also harbor
viruses and thus contribute to enhancing infection with HIV-1
[3,4]. To understand the role of the immune system in HIV
pathogenesis, it is necessary to have an intact host immune system
in small animals infectable with HIV-1. In humans, combinations
of CD4 and CXCR4 or CCR5 can mediate cell entry of HIV-1.
Cells from rats transgenic for human CD4 and human CCR5
were susceptible to HIV-1 entry [5,6]. In this rat model, primary
macrophages and microglia supported some productive HIV-1
replication. However, rat T cells were unable to support virus
spreading due to putative post-transcriptional blocks [5].
Some progress has been made in developing mouse models for
HIV-1. Mice that express HIV transgenes have been generated
using both the full length provirus and individual components of
the HIV-1 genome including Nef, Tat, LTR and Env [7,8,9,10].
Some mouse strains expressing single HIV proteins developed
symptoms of AIDS such as wasting and CD4
+ T cell depletion.
However, full length HIV-1 RNAs are transcribed inefficiently in
mouse cells. hCyclin T1 interacts with HIV Tat protein in a
species-restricted manner to enhance RNA transcription and
processing [11]. In JRCSF (R5 tropic HIV-1) and hCyclin T1
double transgenic mice, increased HIV-1 expression correlated
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+ T cell depletion [12]. In addition to hCyclin T1, hCD4
and hCCR5 or hCXCR4 are necessary for HIV-1 infection of
mouse cells. Transgenic mice that express these human genes have
been generated and reported [13,14]. However, these genes alone
are not sufficient to make mice susceptible to HIV-1. No virus
spreading was observed in vivo for either hCD4/CCR5 or hCD4/
CXCR4 transgenic mice [13,14].
Studies searching for additional factors involved in species-specific
restriction of HIV replication have mainly focused on cell lines such
as NIH 3T3 and A9 cells [15,16,17]. NIH 3T3 cells expressing
hCD4/CCR5/Cyclin T1 supported HIV-1 entry and integration.
Virus assembly was reported to be a major post-integration block,
which could be relieved in mouse-human heterokaryons [18]. A9-
based somatic cell hybrid lines containing human chromosome 2 can
efficiently release infectious virus [17]. The host factors required for
viral release in these systems have not yet been identified. Several
groups have tried to overcome the assembly/release block by altering
the virus, e.g. mutation of matrix protein to enhance membrane
targeting, over-expression of Gag to increase intracellular p24 level,
replacing MA of HIV-1 with that of Murine Leukemia Virus (MLV),
inhibition of HIV-1 RNA over-splicing, and use of the alternative
RNA transport element CTE [19,20,21,22,23,24]. We found that
some lines of 3T3 cells could support efficient Gag processing and
virus release, while other lines could not. Because of these
discrepancies, we were concerned that 3T3 cells may not be an
appropriate model for studying virus release in mouse cells.
Moreover, a mouse model for HIV replication and pathogenesis
will require that T lymphocytes can be infected with the virus. It is
therefore critical that we have a clear understanding of how HIV
replication is affected in primary mouse T cells.
HIV-1 infection in transformed mouse T cell lines was reported
recently [25]. In that study, immortalized mouse T cell lines that
expressed hCD4 and hCCR5 were found to support normal HIV-1
entry, but reverse transcription and nuclear import were reduced as
compared to NIH 3T3 cells or human T cell lines. In the current
study, we have compared the replication of HIV-1 in primary human
and mouse T cells. We found that viral entry, reverse transcription,
and nuclearimportof HIV-1are asefficient in primarymouse T cells
as in human T cells. Although chromosomal integration of HIV-1
proviralDNAwas inefficient in mouseT cells pre-activated with anti-
CD3 and anti-CD28, this block was substantially relieved by
providing a secondary TCR signal after HIV-1 infection. Using
mutant mice, we found that this signal is independent of the pathways
involving PKCh, CARMA1 (CARD 11) and WASp. Treatment with
CsA, which significantly enhances HIV-1 infection in owl monkey
cells [26,27,28], additionally relieved the pre-integration block in
mouse T cells.
Although we were able to overcome blocks in the HIV
replication cycle in murine cells up to proviral integration, we
observed defects in transcription, despite expression of the hCyclin
T1 transgene, and after transcription at the levels of Gag
expression, Gag processing and Gag release. Furthermore,
infectivity of virus released from mouse T cells was lower than
that of virus released from human T cells. These defects
subsequent to HIV integration contributed in aggregate to a
300–500-fold reduction in the titer of virus released from mouse T
cells as compared to human T cells.
Results
Primary T cells from hCD4/CCR5 transgenic mice support
efficient virus entry
We used transgenic mice in which expression of human CD4
and CCR5 was directed by the human CD4 regulatory sequences
(see Materials and Methods [5,12]), in contrast to the Lck
promoter used in published hCD4/CCR5 transgenic mice [13]. In
humans, CD4 is expressed in T cells, macrophages and DCs. To
characterize the cellular expression profiles of hCD4 and hCCR5
in these mice, we performed flow cytometry analysis by co-staining
for mouse CD4, hCD4, and hCCR5. Both transgenes were highly
expressed on mouse CD4
+ T cells in all organs examined,
including blood, mesenteric lymph nodes, spleen, and thymus
(Figure 1A). Mouse bone marrow derived DCs also expressed
hCD4/CCR5 (data not shown). hCCR5 was expressed at a much
higher level on T cells from transgenic mice than on human T
cells. Activation of mouse T cells using plate-coated anti-CD3 and
-CD28 antibodies induced marked down-regulation of hCCR5
from the cell surface (Figure 1A and Discussion).
To measure virus entry, we utilized the Vpr-b-lactamase assay
[29]. Purified mouse and human resting CD4
+ T cells were
infected at different multiplicities of infection (MOIs) with JRCSF
(R5 HIV-1) containing Vpr-b-lactamase. Infected cells were then
loaded with CCF2-AM. The cleavage of CCF2-AM by b-
lactamase was monitored by flow cytometry using the FITC and
DAPI channels, for un-cleaved substrate and cleaved products,
respectively. At MOI of 1, 30% of human T cells supported virus
entry, which was completely blocked by the CCR5 inhibitor TAK-
779. For resting mouse CD4
+ T cells, entry was more efficient,
with about 90% of mouse cells supporting entry (Figure 1B).
Treatment with TAK-779 had only a modest effect, most likely
due to the extremely high level of CCR5 expression at the surface
of T cells in the transgenic mice. Since activation down-regulates
hCCR5 expression, we tested the ability of TAK-779 to inhibit
HIV-1 entry into activated mouse CD4
+ T cells. Under these
conditions, 20% of the cells were infected, and TAK-779
effectively blocked entry (Figure 1C). There was no virus entry
in control experiments with cells from hCD4/hCCR5-negative
mice. Thus, R5 virus can efficiently enter mouse T cells expressing
human CD4 and CCR5. Due to the different levels of hCCR5
between human and transgenic mouse T cells, we chose to use
Vesicular Stomatitis Virus G protein (VSVG)-pseudotyped virus in
subsequent experiments. Entry of VSVG-pseudotyped virus was
similar in human and mouse activated CD4
+ T cells as shown in
Figure S1 and reported previously [25].
Primary mouse T cells support efficient reverse
transcription
We next evaluated the efficiency of reverse transcription
following entry of HIV-1 into mouse T cells. To reduce DNA
carry-over from plasmid used for transfection, virus-containing
supernatants were treated with benzonase [30], which greatly
decreased contamination of the viral prep with DNA, and had no
effect on infectivity (Figure S2).
The kinetics of HIV-1 reverse transcription were studied in
activated mouse T cells at a MOI of 2 (Figure 2A). The results
were similar at higher MOI (data not shown). Early and late
reverse transcription products were monitored by real-time PCR
with primers specific for U5 and U5-Gag. Mouse T cells were
activated for 36 h, collected and frozen down at different time
points post-infection. AZT was used in control cultures to confirm
that the signal was reverse transcriptase dependent. AZT was
added at different time points to inhibit reverse transcription and
samples were collected starting from the next time point. As shown
in Figure 2A, reverse transcription started soon after virus
infection and peaked 12–15 h post-infection. After that, HIV-1
DNA began to be degraded. Late reverse transcription products
followed the same kinetics (Figure 2B). We and others [31,32]
found similar kinetics in human cells (Figure 2C and 2D). We next
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between human and mouse primary T cells. Cell numbers were
calculated based on real-time PCR for the gene encoding 18S
rRNA, using a sequence common to both human and mouse (see
Materials and Methods). The copy number was then normalized
to cell number and was displayed as copy number per cell. Reverse
transcription products were about 50% higher in mouse than in
human T cells (Figures 2C and 2D). However, this increase was
not statistically significant. At the peak of reverse transcription of
HIV-1 (MOI=2), each activated mouse T cell contained
approximately 5 copies of early reverse transcription product
and 3 copies of late reverse transcription product. We conclude
that reverse transcription proceeded as efficiently in mouse T cells
as in human T cells.
Primary T cells from hCyclin T1 transgenic mice support
efficient nuclear import (formation of 2-LTR circles) but
have a defect in integration
A byproduct of the process by which the HIV pre-integration
complex enters the nucleus and gives rise to an integrated provirus
is the formation of 2-LTR circles. 2-LTR circles are formed inside
the nucleus and have been used as an indicator for HIV-1 nuclear
entry [33].
We found no difference in the level of 2-LTR circles formed in
human and mouse T cells after infection with HIV-1 (R7/3-GFP)
(Figure 3A). At MOI of 0.3, there is about 0.1–0.15 copy of 2-LTR
circles in each activated cell. In further support of the detection of
2-LTR circles, the signals were increased about 8–10 fold when
Figure 1. Primary CD4
+ T cells from hCD4/hCCR5 transgenic mice support R5 HIV-1 entry. (A) Single cell suspensions prepared from
mouse blood, mesenteric lymph node, spleen and thymus were analyzed by flow cytometry for the expression of human CD4 and human CCR5. Plots
shown were gated on mouse CD4
+ T cells. Mouse CD4
+ T cells activated by plate-bound anti-CD3/28 were also stained for hCD4/hCCR5expression.
hCyclin T1 transgenic mice served as negative controls. CD4
+ T cells from human PBMCs were also analyzed for comparison. (B) Resting human and
mouse CD4
+ T cells were infected with JRCSF viruses containing Vpr-b-lactamase at MOI of 1. Cells were then loaded with CCF2-AM and incubated at
18–20uC for 2 h (mouse) or overnight (human) before fixation and flow cytometry analysis. FITC channel was used to detect the substrate and DAPI
channel for cleaved product. TAK-779 (1 mM) was used to inhibit CCR5 mediated entry. Cells from non-transgenic mice were used as negative control.
(C) CD4
+ T cells from hCD4/CCR5 mice were activated with plate-bound anti-CD3/28 and analyzed as in panel B. All data represented three
independent experiments.
doi:10.1371/journal.pone.0002035.g001
HIV-1 Replication
PLoS ONE | www.plosone.org 3 April 2008 | Volume 3 | Issue 4 | e2035D116A integrase mutant virus in the same R7/3 backbone was
used (Figure 3A). To study virus integration more directly, we
monitored the expression of GFP after infection of mouse and
human T cells with HIV-GFP, a virus whose nef gene was
replaced with gfp. GFP is expressed from the multiply-spliced
HIV RNA. The multiply-spliced RNAs are exported from the
nucleus independently of the Rev-RRE system, which is thought
to be inefficient in 3T3 cells [21]. In the presence of hCyclin T1,
HIV-GFP virus has been used to study blocks to HIV-1
infection in 3T3 cells [15,16]. Expression of GFP therefore
indicates successful integration, although it can be influenced by
other factors such as LTR promoter activity and mRNA
stability. For this reason, we have also employed a PCR-based
analysis of integrated proviruses in some experiments as
described below, but this was not feasible for comparing mouse
and human cells.
Using HIV-GFP (VSVG) as an indicator virus, successful
integration took place in 30-50% of CD4
+ T cells in PHA-
activated human PBMC. When murine T cells were stimulated
with anti-CD3/28 and infected under conditions similar to those
for human T cells, without secondary TCR signals, infection was
very inefficient, with only about 1.5% of cells becoming infected
(Figure 3B). Under these conditions, mouse T cells are therefore
far less efficient than human T cells in supporting virus
integration.
Secondary TCR signals permit efficient HIV-1 infection of
primary murine T cells
While optimizing conditions for maximum HIV-1 infection of
primary mouse T cells, we found that pre-activation of mouse T cells
was not sufficient to support HIV replication, but when secondary
TCR signals were provided, much of the pre-integration block was
relieved. We sought to understand the role of T cell signaling in the
ability of mouse cells to support infection with HIV.
Primary CD4
+ cells from hCyclin T1 transgenic mice were
purified and stimulated as described above. We then infected the
activated mouse T cells with HIV-GFP (VSVG) at a MOI of 2
(Figure 4A). Three hours post-infection, the cells were washed to
remove virus. Infected cells were then subjected to different culture
conditions. Between 3 and 24 h post infection, cells were cultured
either 1) without anti-CD3; 2) with anti-CD3; 3) with anti-CD3 for
a specified period of time before removal of anti-CD3; or 4) off
anti-CD3 for a specified period of time before being placed on
anti-CD3. IL-2 was maintained in all culture conditions. At 24 h
post-infection, the cells were transferred to a new well with mIL-2
alone. Cells were cultured for an additional 24 h before analysis by
flow cytometry for infection efficiency.
HIV-1 infection efficiency in primary mouse T cells correlated
well with the duration of secondary TCR stimulation after HIV
infection (Figure 4B). Only 2% of cells were infected if the cells
Figure 2. Primary CD4
+ T cells from hCyclin T1 mice support efficient reverse transcription of HIV-1. (A) Kinetics of early reverse
transcription products in mouse T cells. MACS purified CD4
+ T cells from three individual hCyclin T1 mice were activated for 36 h by anti-CD3/28. Cells
were then spin infected with benzonase-treated VSVG-pseudotyped HIV-GFP (MOI=2). 3 h post infection, cells were washed to remove virus and
replated on anti-CD3/28. At different time points, cells were collected, washed and frozen down. DNA was isolated by phenol extraction and Real
Time PCR analysis was preformed. To show the de novo formation of reverse transcription products, AZT (15 mM) was added at different time points
and cells were collected as above starting from the next time point (Dashed lines). Real Time-PCR was performed using primers and probes specific
for 18S rRNA (for cell number) and R-U5 (for early reverse transcription product). The copy number of reverse transcription product was then
normalized to cell number and displayed as copy number per cell. (B) Kinetics of late reverse transcription products. Samples from panel A were
subjected to Real Time-PCR using primers and probes specific for U5-Gag. (C, D) Activated CD4
+ T cells from three mice were infected and analyzed
for early (panel C) and late reverse transcription (panel D) products as described in panel A. For comparison, PHA activated human PBMC CD4
+ T cells
from three donors were infected and analyzed in parallel. All values represent the arithmetic means 6SD. Data represent two independent
experiments, each with cells from three human donors or three mice.
doi:10.1371/journal.pone.0002035.g002
HIV-1 Replication
PLoS ONE | www.plosone.org 4 April 2008 | Volume 3 | Issue 4 | e2035were removed from antibody at 3 h post-infection. Infection level
increased linearly with the incubation time on plate-bound
antibodies and reached a maximum of 25% after 24 h
(Figure 4B). The infection efficiency did not increase further if
cells were stimulated beyond this 24 h window (data not shown).
Addition of anti-CD28 did not further increase mouse T cell
infectivity (Figure 4C)
The effect of secondary stimulation was initially observed in
human cyclin T1 transgenic mice. To determine if the activation
signals werealso necessaryin primary T cells from wildtype mice, we
used an HIV-1 construct in which Cytomegalovirus (CMV)
promoter-driven gfp replaced nef. While this virus (HIV-CMV-GFP)
gave similar result to HIV-GFP virus in primary T cells from
hCyclinT1 transgenic mice, it bypassed the need for hCylin T1 in
mouseTcells.AsshowninFigure 4C,inwildtypeB6orBalb/cmice
activation signals were also necessary for maximum infection,
although this was lower than observed in the mixed background of
the transgenic mice. Removal of anti-CD3 and CD28 after HIV-1
infection reduced the percentage of GFP
+ T cells 5–10-fold to 0.5–
1%. Treatment with anti-CD28 or IL-2 was neither necessary nor
sufficient for enhanced HIV-1 infection. We further tested if phorbol
myristate acetate (PMA) and ionomycin could replace anti-CD3 in
promoting HIV replication. Mouse T cells were pre-activated with
anti-CD3 and anti-CD28. After HIV-1 infection, PMA and
ionomycin were added instead of anti-CD3. As shown in
Figure 4D, treatment with PMA alone fully recapitulated the role
of anti-CD3.
To determine if the effect of TCR signaling was unique to HIV-
1, we treated mouse CD4
+ T cells in the same way during
infection with MLV. At high MOI, infection efficiency was similar
with or without the secondary TCR signal (Figure 4E). At low
MOI, removal of the anti-CD3 antibody at 3 h post-infection
resulted in a 50% reduction in infection (Figure 4E). The
secondary TCR signal therefore enhances infection of murine T
cells with both MLV and HIV-1, but appears to have a greater
effect upon infection with HIV-1.
To further characterize the requirement for TCR signaling, we
infected activated mouse T cells and re-plated them without anti-
CD3 stimulation. At the peak of reverse transcription (12 to 15 h
post-infection), we re-plated the cells on anti-CD3 (condition (4) in
Fig. 4A). Antibody was removed at 24 h post infection and cells
were assayed at 48 h post-infection. Under these conditions, 70–
80% of the maximum infection efficiency was obtained, as
compared to 7–10% if CD3 stimulation was not provided
(Figure 4F).
To establish which stage of the HIV replication cycle was
enhanced by TCR signaling, we analyzed reverse transcription
under the various stimulation conditions. Late reverse transcrip-
tion products were decreased about 2–3 fold in the absence of
secondary stimulation (Figure 4G), but the reduction was more
modest than the 10-fold effect in infection efficiency. To measure
the difference in integrated provirus, a two round amplification
strategy was employed, with the first round using primers specific
for HIV-1 Gag and SINE B2 sequences [34,35] and the second
round using primers and probes specific for HIV-1 U5. Integrated
provirus levels were reduced 5–8 fold in the absence of a
secondary TCR signal (Figure 4H). As pre-activated T cells are
actively engaged in cell proliferation (at least once per 24 h) and
we did not find consistent down-regulation of 2-LTR circles (data
not shown), we do not believe that nuclear import of HIV-1 DNA
was affected in the absence of the secondary TCR signal. These
results suggest that the activation signals are important for both
reverse transcription and other pre-integration steps (see Discus-
sion). It has been reported that duration of anti-CD3/28 and IL-2
signaling is important for efficient HIV-1 infection of human T
cells [36]. Our results indicate that activation of primary mouse T
cells prior to infection with HIV is not sufficient for viral
replication, and that secondary TCR signals are required for
post-entry events.
Ligation of the TCR/CD3 complex activates several distinct
signaling pathways, including the NF-kB pathway that is
dependent on PKC-h and CARMA1. To determine whether this
pathway has a role in promoting steps in HIV replication, we
examined infection of CD4
+ T cells from mice deficient in PKC-h
or CARMA1. Primary T cells from both strains of mutant mice
supported HIV-1 infection as long as secondary TCR signals were
provided (Figure 4I). Thus, signaling pathways involved in efficient
integration of the HIV-1 provirus are independent of these
upstream effectors of NF-kB activation. Wiskott-Aldrich Syn-
drome protein (WASp)-mediated cytoskeleton reorganization is
another pathway downstream of the TCR and is important for
immune synapse formation [37]. We obtained a similar result with
T cells from WASp-deficient mice (Figure 4I) indicating that this
pathway is not involved in HIV-1 replication.
The role of secondary TCR signaling in HIV-1 infection is
specific for primary mouse T cells
We wished to determine whether a secondary TCR signal also
promotes HIV-1 infection of mouse T cell lines and primary
human T cells, as it does with primary mouse T cells. Infection of
mouse T cell lines 1010-5 and AKR with HIV-CMV-GFP
(VSVG) at MOI of 2 did not require the secondary TCR signals
provided by anti-CD3 or PMA (Figure 5A). Similar results were
Figure 3. Primary CD4
+ T cells from hCyclin T1 mice support
efficient nuclear import of HIV-1 but less efficient integration.
(A) CD4
+ T cells from hCyclin T1 transgenic mice and human donors
were activated and infected with VSVG-pseudotyped R7/3-GFP at MOI
of 0.3 or its D116A integrase mutant virus with similar amount of RT as
described in Materials and Methods. At 24 and 48 h post infection, cells
were collected and subjected to real-time PCR specific for 2LTR circles.
(B) CD4
+ T cells from hCyclin T1 transgenic mice were activated and
infected with VSVG-pseudotyped HIV-GFP at MOI of 2 as described in
Materials and Methods. Cells were removed from anti-CD3/28 antibody
at 3 h post infection. Infection was assessed by GFP expression using
flow cytometry at 48 h post-infection. For comparison, activated human
CD4
+ T cells were infected and analyzed in parallel. All data represented
three independent experiments.
doi:10.1371/journal.pone.0002035.g003
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shown in (A). MACS purified CD4
+ CD25
2 T cells were activated by anti-CD3/28 for 36 h before spin-infection with VSVG-pseudotyped HIV-GFP.
Infected cells were then subjected to different culture conditions. Between 3 and 24 h post infection, cells were cultured either A1) without anti-CD3;
A2) with anti-CD3; A3) with anti-CD3 for a specified period of time before removal of anti-CD3; or A4) off anti-CD3 for a specified period of time
before being placed on anti-CD3. Filled bars show the presence of anti-CD3 while open bars show the absence. At 24 h post infection, all cells were
cultured with mIL-2 alone. Infection was assessed by GFP expression using flow cytometry at 48 h post-infection. (B) Activated CD4
+ T cells from
hCyclin T1 transgenic mice were subjected to the analysis shown in panel A condition 3. Infected mouse T cells were incubated on anti-CD3/28
antibody first and then removed from antibody at different time point as indicated on the x-axis. (C) Activated CD4
+ T cells from wild type C57/BL6
(B6) and Balb/c mice were infected with HIV-CMV-GFP (VSVG) at MOI of 2. After infection, cells were provided with anti-CD3/28 (black bar), anti-CD3
(grey bar) or no antibody (open bar). (D) Analysis was as in panel A condition 2, except that PMA and ionomycin were used in place of anti-CD3. (E)
Analysis was done as in panel B except that MLV was used. (F) Analysis as in panel in panel A condition 4. At 3 h or 6 h post-infection, cells from
hCyclin T1 mice were transferred to wells without anti-CD3. At 12 h or 15 h post-infection, these cells were transferred back to wells with anti-CD3. As
controls, cells were treated under condition A1 and A2 at 3 h post infection. (G) CD4
+ T cells from hCyclin T1 transgenic mice were infected with HIV-
GFP (VSVG). Cells were taken off anti-CD3/28 at 3 h post-infection and transferred to wells without or with anti-CD3 as in panel A conditions A1 and
A2. At different time points indicated on the X-axis, cells were collected and subjected to Real Time-PCR specific for U5-Gag as described in the
legend to Figure 2B. (H) CD4
+ T cells from hCyclin T1 transgenic mice were infected with HIV-GFP (VSVG). Cells were taken off anti-CD3/28 at 3 h post-
infection and transferred to wells without or with anti-CD3 as in panel A conditions A1 and A2. At two days post infection, cells were collected and
subjected to two–round PCRs, as described in Materials and Methods, to quantify the integrated proviruses. (I) CD4
+ T cells from Wasp
2/2, Pkch
2/2
and Carma1
2/2 mice were activated with anti-CD3/28 in the presence of 100 U/ml mIL-2. After infection with HIV-CMV-GFP (VSVG), cells were
provided with secondary anti-CD3 or no antibody as shown as in panel A conditions 1 and 2. All data represented three independent experiments.
doi:10.1371/journal.pone.0002035.g004
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shown).
The majority of mouse T cells from 6–8 week old mice are naı ¨ve
whereas the majority of T cells from human PBMCs are memory
T cells. For a better comparison with mouse T cells, we isolated
CD4
+ T cells from human cord blood, as most of these cells are
naı ¨ve. As shown in Figure 5B, secondary treatment with PMA or
anti-CD3 had no effect on infection of primary human T cells. In
addition, we obtained similar results when total CD4
+ T cells from
human PBMCs were used (data not shown).
CsA further relieves the pre-integration block in primary
mouse T cells
In the course of our experiments, we found that Cyclosporin A,
when added 3 h post-infection, increased infection efficiency from
21% (DMSO) to 35% at 0.1 mg/ml CsA and 42% at 1 mg/ml CsA
(Figure 6A). However, CsA could not substitute for TCR signals,
but instead amplified the effect of TCR signals (Figure 6B). In the
absence of TCR signals, CsA only modestly increased the infection
efficiency from 2% to 5%. We further tested the effect of CsA on
Wasp
2/2 and Pkch
2/2 mice. As shown in Figure 6C, the TCR
signaling pathways that require these proteins are not involved in
the mechanism of CsA mediated enhancement of HIV-1 infection.
Primary T cells from hCyclin T1 transgenic mice have
defects in HIV-1 transcription and translation
The relief of the pre-integration block in primary mouse T cells
enabled us to further characterize the post-integration steps in the
HIV-1 replication cycle. The expression of hCyclin T1 enhances
the transcription of HIV-1 RNA in primary mouse T cells [12].
When infected with HIV-GFP (VSVG), in which GFP is driven by
the LTR promoter, there were very few detectable GFP positive T
cells in wild type mice as compared to 15–25% in hCyclin T1
transgenic mice (data not shown). To establish whether the
expression of hCyclin T1 was sufficient to relieve the transcription
block in mouse T cells, we further analyzed the level of total HIV-
1 RNAs in hCyclin T1 transgenic T cells as compared to human T
cells by real-time PCR using primers specific for U5 sequences in
the LTR (Figure 7A). Single round infection with HIV-1 (VSVG)
was performed in primary mouse and human T cells. The U5
RNAs were normalized to the 18S rRNA and compared between
total human and mouse cells. After normalization to infection
efficiency, about 10 fold more HIV-1 RNAs were detected in
infected human T cells than mouse T cells.
Subsequent steps in the HIV-1 replication cycle were further
examined. Human T cells express full-length Gag proteins and
efficiently process them (Figure 7B). In mouse T cells infected with
an efficiency of 20–25%, expression of Gag was reduced
approximately 70-fold compared to human T cells (Figure 8A)
and Gag remained unprocessed (Figure 7B).
Primary T cells from hCyclin T1 transgenic mice have
defects in virus release and infectivity
To measure the efficiency of p24 release, the ratio of
extracellular to intracellular p24 in HIV-infected mouse and
human T cells was determined by ELISA. CD4
+ T cells were
Figure 5. Role of secondary TCR signals is specific for mouse primary T cells. (A) mouse T cell lines 1010-5 and AKR were infected with HIV-
CMV-GFP (VSVG) at MOI of 2. Three hours post infection, cells were transferred to wells with coated anti-CD3, no antibody, or PMA. Twenty-four hours
post infection, cells were transferred to new wells with IL-2 alone. FACS analysis for GFP was done 48 h post infection. (B) CD4
+ T cells from two
human cord blood donors were activated with anti-CD3/28 for 36 h as described in Materials and Methods. Cells were infected and analyzed as in
panel A.
doi:10.1371/journal.pone.0002035.g005
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mouse CD4
+ T cells express and release low levels of p24, small
amounts of residual input virus can lead to a false signal of viral
release. To avoid thiscontaminating signal, the cells weretreated with
pronase to remove virus bound to the outside of the cell after
infection. Additionally, cell death could lead to release of p24 into the
medium, so cell viability was carefully monitored. We excluded any
experiments in which there were fewer than 70-80% live cells at 2 d
post infection. We could consistently achieve this when using highly
purified CD4
+ mouse T cells that were depleted of CD25
+ cells. The
release of p24 was reduced in mouse T cells as compared to human
cells.The ratio of extracellular to intracellular p24 averaged 0.015 for
mouse T cells versus 0.4 for human T cells (Figure 8A).
To measure virus infectivity, we used a reporter cell line
(Tzmbl), which is a HeLa cell line stably transfected with LTR-
luciferase and hCD4/CXCR4/CCR5 [38]. Mouse and human T
cells were infected with JRCSF (VSVG) and the supernatants were
used to infect Tzmbl cells. Mouse T cells released 300–500-fold
lower infectious virus than human T cells. After normalization to
the level of p24, virus released from mouse cells had 6–10 fold
lower infectivity than that from human T cells (Figure 8B).
Primary T cells from hCyclin T1 transgenic mice have a
defect in virus budding
To view the assembly and budding of HIV, electron microscopy
was performed for mouse and human T cells infected with HIV-1.
The process of virus budding and release can be observed at the
plasma membrane in human T cells (Figure 9, upper panels).
Interestingly, viruses were not released from the entire plasma
membrane. Instead, release was localized to a few discrete areas.
Virus budding through the multi-vesicular body (MVB) was not
detected.
No virus was detected budding from the plasma membrane in
mouse T cells (Figure 9, lower panels), but some particles were
observed budding into the nuclear membrane. In other cells,
viruses were observed to assemble and bud randomly into or from
intracellular membranes (Figure 9, lower panels).
Discussion
We have studied HIV-1 replication in primary mouse T cells
and compared the efficiency of each step in mouse cells with that
in primary human T cells. Expression of hCD4, CCR5 and
Figure 6. CsA further sensitizes the TCR effect on the pre-integration block in mouse T cells. (A) CD4
+ T cells from hCyclin T1 transgenic
mice were activated and infected with HIV-GFP (VSVG). Three hours post infection, cells were transferred to wells coated with anti-CD3 together with
0.1 mg/ml CsA, 1 mg/ml CsA or DMSO control. Twenty-four hours post infection, cells were washed twice with PBS and transferred to new wells with
IL-2 alone. FACS analysis for GFP was done 48 h post infection. (B) Analysis was as in panel A except that at 3 h post infection cells were transferred to
wells coated with or without anti-CD3, together with 0.1 mg/ml CsA. (C) CD4
+ T cells from wild type, Pkch
2/2 and Wasp
2/2 mice were activated and
infected with HIV-CMV-GFP (VSVG). Three hours post infection, cells were transferred to wells coated with anti-CD3, together with 0.1 mg/ml CsA,
Cells were then analyzed as in panel A.
doi:10.1371/journal.pone.0002035.g006
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greatly enhanced viral transcription. In this study, we relieved the
block prior to integration by providing TCR signals and
Cyclosporin A after HIV-1 infection. However, multiple addition-
al blocks were found to exist in primary mouse T cells. These
blocks together prohibit release of high titers of infectious HIV-1
sufficient for virus spreading.
Virus Entry
Transgenic constructs containing enhancers, promoter, and
silencer of the hCD4 gene enable high expression of hCD4 and
hCCR5 on the surface of mouse CD4
+ T cells, macrophages and
dendritic cells in the transgenic mice used in this study. There are
very few cells that are hCD4 or hCCR5 positive but mouse CD4
negative (Data not shown). While this is a good system to study
virus entry, CCR5 is expressed at a much higher level on all mouse
CD4
+ T cells, in contrast to human T cells, in which it is expressed
primarily on memory rather than naı ¨ve T cells [39]. Thus, the
transgenic mouse cells were more permissive than human cells for
virus entry. This transgenic model may hence lead to more severe
T cell depletion if the other blocks to HIV-1 replication can be
solved, and a better model to use may be hCCR5 knock-in mice.
The expression level of hCCR5 was down regulated by
activation using coated anti-CD3/28 antibodies. This is consistent
with previous studies showing that anti-CD28 down-regulates
CCR5 in human T cells, inhibiting R5 tropic HIV-1 infection
[40]. However, in mouse cells, degradation rather than synthesis of
CCR5 RNA may be affected, as hCCR5 expression was not
driven by the endogenous promoter. CCR5 down-regulation
resulted in reduction in entry of HIV-1 into activated mouse T
cells. This may not be a problem in vivo as HIV-1 can enter resting
cells, in which reverse transcription is initiated. Subsequent steps of
the HIV life cycle can then be completed upon T cell activation
[41,42]. We also note that hCCR5 staining with antibody did not
Figure 7. Analysis of HIV-1 RNA and proteins in infected primary mouse T cells. Primary CD4
+ T cells from hCyclin T1 mice (mT) or human
PBMCs (hT) were infected with VSVG-pseudotyped HIV-GFP at MOI of 2 in the presence or absence of AZT. Forty-eight hours later, cells were
collected. (A) Total RNA was extracted from infected cells. Infection in the presence of AZT served as negative control for de novo expression of RNA.
cDNA formation in the absence of reverse transcription enzyme served as negative control for contaminating DNA. Real Time-PCR was performed
using primers and probes specific for 18S rRNA and R-U5 (HIV). The ratio of HIV to 18S rRNA was further normalized by infection efficiency to show
the relative copy numbers of HIV RNAs per infected cell. hCyclinT1 mice gave an average of 20% infection efficiency, while human T cells gave an
average of 50%. (B) Total cellular proteins were analyzed on 12% acrylamide gels and subjected to western blot analysis with anti-p24 monoclonal
antibody. Endogenous a-tubulin was analyzed on the same membrane as a loading control. As a comparison, stable clones derived from 3T3/Cyclin
T1 infected with HIV-GFP (VSVG) were analyzed in parallel.
doi:10.1371/journal.pone.0002035.g007
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For example, a much lower percentage of human T cells can be
stained with hCCR5 antibody, while they supported 30% of virus
entry. This could be due to the need for few hCCR5 molecules to
obtain virus entry.
Reverse Transcription
Using HIV-1 pseudotyped with VSVG to normalize entry in
mouse and human T cells, we found that HIV-1 reverse
transcription had the same kinetics in the two species. Reverse
transcription products peaked around 12–15 h, which was
Figure 8. Primary CD4
+ T cells from hCyclin T1 mice do not release virus efficiently. Activated CD4
+ CD25
2 T cells were infected with
VSVG-pseudotyped HIV-GFP or JRCSF at MOI of 2. Three hours post-infection, cells were washed and plated on anti-CD3 with mIL-2. Twenty-four
hours post-infection, cells were treated with pronase as described in Material and Methods. Infected cells were incubated at 37uC for an additional
24 h and checked by flow cytometry to assess viability. Cells and supernatants were collected after centrifugation. For comparison, activated human
CD4
+ T cells were analyzed in parallel. (A) p24 levels in cell lysates and supernatants after infection with HIV-GFP (VSVG). (B) Infectivity of virus
released from cells infected with JRCSF (VSVG) was measured by adding supernatant to Tzmbl reporter cell lines. At 16 h after infection, AZT and TAK-
779 were added to Tzmbl to prevent a second round of infection. Firefly luciferase assays were performed at 48 h post-infection. Luciferase signals in
mock infection control were subtracted from those in infected cells. The data represented experiments using cells from five human donors or five
mice. p24 levels in the supernatant (by ELISA) were used for normalization.
doi:10.1371/journal.pone.0002035.g008
Figure 9. Defective virus budding in HIV infected mouse T cells. Electron microscopy of infected human (upper panel) and mouse (lower
panel) T cells. On the left, low magnification of infected cells; in the middle, higher magnification of infected cells; on the right (for mouse T cells),
aberrant budding of VLP into nuclear membranes is shown. Red arrows indicate assembling viral particles, while blue arrows indicate inner and outer
nuclear membranes.
doi:10.1371/journal.pone.0002035.g009
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unknown mechanism. From these data, we are able to conclude
that there is no block to reverse transcription in mouse cells. These
conclusions are supported by a recent publication which also
found no block to reverse transcription in primary mouse T cells
[43]. However, reduction of reverse transcription products was
observed in mouse T cell lines [25]. This may be because of the
use of high MOI of viruses or if mouse T cell lines behave
differently from primary T cells. The differences between primary
mouse T cells and T cell lines may be due to genetic background
or to transcriptional changes that occurred upon transformation.
Nuclear import and integration
We found similar levels of 2-LTR circles in HIV-infected mouse
and human T cells, consistent with equivalent nuclear import of
preintegration complexes. Integration is more difficult to compare
between mouse and human cells. One way to quantify integration
of HIV-1 is to separate genomic from small molecular weight
DNA and quantify the integrated provirus. This experiment needs
to be carefully controlled since a small amount of contamination
with un-integrated HIV DNA can influence the results. To
measure integration in human cells, many groups have taken
advantage of the abundant Alu sequences which are found, on
average, every 500bp throughout the genome [44]. SINE B2
sequences in mouse cells are less frequent; however, they can be
used to compare the efficiency of HIV-1 integration among mouse
cell samples. Because HIV-1 integration cannot be quantitatively
compared between species by using these methods, we have
chosen to compare integration efficiency between mouse and
human by infecting cells with HIV-GFP and using GFP expression
as a surrogate marker for integration, an approach used previously
to study blocks in the HIV replication cycle in 3T3 cells [15,16].
We found that Cyclosporin A can double the infection efficiency
of primary mouse T cells at a concentration that inhibits NFAT
signaling. CsA probably works on steps after reverse transcription,
since it had similar effect on cells treated between 12 h and 24 h
post-infection (data not shown). It was reported that interruption
of the interaction between HIV-1 CA and Cyclophilin A has
opposite effects in human cells and non-permissive cells from other
species [26,27,28]. Thus, CsA accentuated the restriction of Ref1
(Trim5a or other host factors [45]) in human cells, while greatly
relieving the restriction of LV-1 in other species. For example,
treatment of owl monkey cells with CsA increased the proportion
of HIV-1 DNA in the nucleus and led to a 100–1000-fold increase
in virus titer [26,27,28]. It was reported that Cyclosporin A
enhanced the infection efficiency in primary mouse bone marrow
cells but had no effect on primary mouse splenic T cells [46]. The
failure to detect the enhancement in mouse T cells was likely due
to the absence of TCR signals, which obscured the effect of
Cyclosporin A (Figure 6B). We speculate that there is a mechanism
similar to that in non-human primates, involving Cyclophilin A
blockade of mouse T cell infection with HIV-1. It will be
interesting to determine whether the G89V HIV mutant, whose
CA cannot interact with Cyclophilin A, has a higher infection
efficiency in mouse T cells. Mouse cells do not have a Trim5a
ortholog, but other related proteins may be involved in this host
restriction.
Activation signals for HIV-1 infection
In the process of optimizing conditions for HIV-1 infection of
mouse T cells, we found that additional TCR signals were
essential, in a limited time window, for infection of pre-activated T
cells. In the absence of a secondary stimulus late reverse
transcription products were decreased 2–3 fold. Although this
suggests that TCR signals can enhance the reverse transcription of
HIV-1, this is not likely to be the critical step affected, since
providing TCR signals at the peak of reverse transcription did not
result in a rebound of reverse transcription (data not shown), but
rescued infection to an average of 70% of the maximum efficiency
(Figure 4F). The TCR signals increased the efficiency of HIV-1
integration in mouse T cells about 5–8 fold (Figure 4H). It remains
possible that TCR signals also affect steps subsequent to HIV
integration. However, similar results were obtained using reporter
HIV viruses whose GFP expression was driven by either CMV or
LTR. Moreover, there was no change in GFP expression in
infected primary mouse T cells when the secondary TCR signal
was provided at 5 days instead of 3 hours post infection (data not
shown). An accurate assessment will require a reliable technique
that can quantify and compare levels of the integrated provirus
between primary mouse and human T cells.
In a recent paper describing HIV-1 infection of primary mouse
T cells from hCD4/CXCR4 transgenic mice, a significant pre-
integration block was reported [43]. The block was ascribed to
mis-localization of HIV-1 integrase protein from nucleus to the
cytoplasm, but this was assessed in mouse 3T3 cells. We and others
[15,16]] have not observed a pre-integration block in 3T3 cells,
suggesting that the localization of integrase protein is unrelated to
successful nuclear import or integration. The major difference
between our results and those in the recent paper most likely lies in
the continued TCR stimulation that we employ, although it
remains possible that there is an effect on integrase localization in
the primary T cells.
Identification of the TCR signaling pathways involved in
relieving the pre-integration blocks may provide further insight
towards developing a mouse model for HIV-1 replication. It
remains to be determined if antigen-presenting cell-T cell
interaction is sufficient to provide the secondary TCR signals.
Further experiments must be performed to establish which
molecules downstream of the TCR can function to increase
HIV infection. PKCh and CARMA1, which are required for NF-
kB activation in T cells, as well as WASp are dispensable for
efficient HIV infection after TCR stimulation. However, the
PI3K-AKT pathway may be involved in promoting proviral
integration [47]. PI3K inhibitor, added 1 h post-infection of
primary mouse T cells, completely blocked HIV-1 infection in the
presence of anti-CD3/28 and IL-2 (Figure S3). It is known that at
different concentrations PI3K inhibitor can block both PI3K and
its downstream kinase [48]. Additionally, PI3K is involved in DNA
damage repair. Molecules involved in the DNA damage repair
pathway have been implicated in HIV-1 integration, although
these results are controversial [49,50,51]. Our preliminary results
thus suggest that the PI3K/Akt, but not the NF-kB, pathway is
important in facilitating post-entry steps of HIV replication in
murine T cells.
The effect of secondary TCR signaling is not necessary for
mouse T cell lines and primary human T cells. This implies that
there is a species-specific factor(s) responsible for the pre-
integration block in primary mouse T cells. In mouse cell lines,
the TCR signals may have been bypassed upon transformation,
and hence such stimulation has little effect. We note a much
higher infection efficiency found in the mouse T cell lines used in
this study, compared to another report indicating significant pre-
integration blocks [25]. This may be due to the different genetic
backgrounds between cell lines, similar to the observation shown
in Figure 4C that primary cells from B6 and Balb/c are less
infectable than cells from transgenic or knockout mice with mixed
background. Further work needs to be done to identify the specific
protein(s) involved in the TCR-dependent increase in HIV-1
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lated mice that are permissive for single round HIV infection and
may provide a better understanding of the pre-integration steps in
HIV-1 infection.
Virus release
The last step of the HIV-1 life cycle is virus budding and release.
HIV-1 transgenic mice can potentially be used to study this and
other post-gene expression steps. However, HIV has been shown
to be toxic for CD4
+ T cells [12,52,53], so mature CD4
+ T cells in
the HIV transgenic mice have potentially undergone changes to
allow them to survive. For this reason, we assessed particle
maturation and release in freshly-infected T cells from hCyclin T1
transgenic mice. Because primary mouse T cells are very sensitive
to apoptosis and activated primary CD4
+ T cells are prone to
activation-induced cell death, we used low viral MOI and
optimized conditions to avoid cell death. We used VSVG-
pseudotyped virus for these assays as the Env protein of HIV-1
was found to be more toxic to primary T cells than VSVG, as
indicated by apoptosis analysis based on AnnexinV staining (data
not shown). Additionally, removal of CD25
+CD4
+ regulatory T
cells resulted in substantial increase in survival of CD4
+ T cells.
Under these conditions, we observed a block in release of HIV-1
from mouse cells.
Compared to virus released from human T cells, virus released
from primary mouse T cells was 6–10 fold less infectious.
Compounding this reduced infectivity of released particles was
the dramatic decrease in intracellular Gag. It is possible that viral
restriction by host factors is more significant when virus
production is low. We will have a better understanding of
infectivity of particles released from mouse cells once we have
improved the transcription and processing of HIV-1 Gag protein.
Electron microscopy further confirmed the release block in
mouse primary T cells. In these experiments, virus budding
appeared to be abnormal in mouse T cells. We observed virus
particle budding into the nuclear membrane and inducing swelling
between the inner and outer nuclear membrane. We failed to
observe virus budding out of the plasma membrane. This is in
contrast to human cells where we easily observed viral release from
the plasma membrane.
In conclusion, we have demonstrated that primary T cells from
hCD4/CCR5/Cyclin T1 mice support efficient HIV-1 virus
entry, reverse transcription and nuclear import. TCR signals were
found to be essential to relieve a pre-integration block in mouse T
cells, and this block was further relieved by CsA. The effect on
proviral integration was confined to primary T cells, highlighting
the importance of studying such cells in addition to immortalized
cell lines in our efforts to acquire a better understanding of HIV
replication. Our results also indicate that additional host factors
wait to be identified to solve inefficient transcription, Gag
translation, Gag processing and virus release.
Materials and Methods
Mice and Plasmids
Human CD4/CCR5/Cyclin T1 transgenic mice were gener-
ated individually and bred into double or triple transgenic lines.
Constructs included a human genomic CD4 minigene [54] and
human CCR5 and Cyclin T1 cDNAs under the control of murine
Cd4 enhancer and human CD4 promoter, silencer, and monocyte-
lineage enhancer [5,12]. Phenotype of hCD4 and hCCR5
transgenic mice was assessed by flow cytometry analysis of mouse
blood stained with Pacific Blue-mCD4, APC-hCD4 and APC-
Cy7-hCCR5 antibodies. hCyclin T1 transgenic mice were
identified by PCR analysis of DNA extracted from mouse tails.
Primers used were GAATACCGC GCGAAGCAT (forward) and
CCTTTTACGAG TAGAACTGGAAGAG (reverse). Wild type
Balb/c and C57BL6 mice were purchased from Taconic. All
animal experiments were performed in accordance with approved
protocols from the NYU Institutional Animal Care and Usage
Committee. HIV-CMV-GFP plasmid was made by replacing the
nef gene in the HIV-HSA vector [55] with CMV-GFP utilizing NotI
and XhoI sites. CMV-GFP was amplified from pEGFP-C1 vector
by PCR using primers as follows: forward ATAA-
GAATGCGGCCGCTTAATAGTAATCAATTACGG, reverse:
CCAGCTCGAGATTACTTGTACAGCTCGTCCATGCCG.
pM310 plasmid encoding Vpr-b-lactamase was obtained from
Michael D. Miller (Merck). R7/3-GFP and its D116A integrase
mutant plasmids were obtained from Michael Topper and Mark
Muesing (Aaron Diamond AIDS Research Center) [56]. Plasmid
for 2-LTR circles was obtained from Mark Sharley (UMass).
T cells
Human CD4
+ T cells were purified from peripheral blood and
cord blood obtained from the New York Blood Center. The blood
procurement from healthy donors for this study has been reviewed
and approved by the New York University School of Medicine
Institutional Review Board. Mononuclear cells were isolated by
Ficoll-Paque (GE Healthcare) gradient centrifugation. CD4
+ Tc e l l s
were further purified by positive selection using anti-hCD4 magnetic
microbeads (1:20 dilution) and MACS column (Miltenyi Biotech),
following the manufacturer’s protocols. For mouse primary CD4
+ T
cells, single-cell suspensions from spleen and mesenteric lymph nodes
were first enriched by staining with PE-conjugated anti-mCD8,
mB220, mCD11b, mCD11c, mCD25 (all 1:100 dilution) and
mTer119 (1:66 dilution), followed by incubation with anti-PE
magnetic microbeads and depletion through MACS column. The
depleted fraction was positively-selected by anti-mCD4 magnetic
microbeads to get .99% pure resting primary mouse CD4
+ T cells.
T cells were cultured in RPMI 1640 (Invitrogen) supplemented with
10% heat-inactivated Fetal Calf Serum (Hyclone), 2 mM L-
glutamine, 100 u/ml penicillin, 100 mg/ml streptomycin, and
50 mM b-mercaptoethanol. Cells were plated at a density of 1–
1.2610
6 per well of a 24-well culture plate.
Virus stocks
HIV-1 stocks were generated by calcium phosphate transfection
of 2.5610
6 293T cells in 10 cm plate with 15 mg virus vector
(JRCSF, HIV-GFP, HIV-CMV-GFP, R7/3-GFP or its D116A
mutant) and 5 mg Env vector (JRCSF or VSVG) as indicated by
envelope pseudotyping. Virus supernatants were collected 48 h
post transfection and treated with Benzonase (15U/ml, EMD
Bioscience) in 1x buffer (50 mM Tris-HCl pH 8.0, 1 mM MgCl2,
and 0.1 mg/ml BSA) for 15 min at 37uC. Aliquots of virus were
frozen at 280uC until use. Virus titer was determined by serial
dilutions on GHOST/CCR5 or GHOST/parental cell lines in
the presence of polybrene (8 mg/ml). R7/3 GFP and its D116A
mutant viruses were also titrated with reverse transcriptase assay
(RT assay kit, Roche) to ensure that similar amounts of virus were
used for infection in Figure 3A for detecting 2LTR signals. Flow
cytometry analysis was done 36 h after infection of GHOST cells
to assess percentage of GFP positive cells. MLV was produced by
transfection of Phoenix E cells with MSCV retrovirus vector
expressing Cre-GFP. Titer was titrated on 3T3 cells.
T cell activation and infections
For human T cell analysis, CD4
+ T cells were cultured with
PHA (5 mg/ml, Sigma) and hIL-2 (30 Unit/ml, Roche) for two
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alone for 1 day before infection. For human cord blood T cells,
CD4
+ T cells were activated by cross-linking with plate-bound
anti-CD3/CD28 antibody (5 mg/ml each, eBioscience). The
plates were first coated with goat anti-mouse IgG (10 mg/ml,
Caltag). For mouse T cell analysis, CD4
+ T cells were cultured
on anti-CD3/28 (clone 145-2C11 for anti-CD3, clone 37N for
anti-CD28, Memorial Sloan-Kettering Cancer Institute, 5 mg/
ml each, 500 ml per well in 24-well-plates coated at 37uC for 2–
3 h) for 36 h before infection. Virus was added to cells together
with polybrene (8 mg/ml). Spin-infection was done by centrifu-
gation at 2,000 rpm for 1 h at R.T. Cells with virus were
incubated at 37uC for 2 additional hours and then washed twice
to remove virus. Human or mouse IL-2 (30 Unit/ml,
eBioscience) was added and maintained all the time after
infection. 100 unit/ml of mIL-2 was used during the activation
and culture of CD4
+ T cells purified from Pkch
2/2 and
Carma1
2/2 mice.
Flow Cytometry
Flow cytometric analysis was performed on an LSR II
cytometer (BD Biosciences) and analyzed using FlowJo software
(Tree Star Inc.). Antibodies used in this study were obtained
through eBioscience or BD Biosciences.
Entry assay
Viruses containing Vpr-b-lactamase were generated by co-
transfection of 10 mg pM310 with 15 mg JRCSF or 15 mg HIV-
GFP (Env
2) plus 3 mg VSVG into 293T cells in 10 cm plates using
the calcium phosphate method. Virus containing supernatants
were concentrated by ultracentrifugation at 25,000 rpm for 1.5 h
at 4uC and resuspended in 200 ml of RPMI medium. Virus titer
was determined on GHOST cell lines [57]. For entry assay, 0.5–
1610
5 cells per well in 96-well-plate were spin-infected with
different MOIs of virus for 1 h and incubated for another 2 h at
37uC to ensure complete virus entry. Cells were washed once with
CO2-independent medium. Cells in each well were provided with
30 ml loading reagent (6x, Protocol for Beta-lactamase loading
solutions, Invitrogen) and 150 mlC O 2-independent medium
supplemented with 10% serum and IL-2. Cells were incubated
at 18–20uC for 2 h for mouse T cells and overnight for human T
cells. After incubation, cells were washed with CO2-independent
medium and fixed with PFA. Entry efficiency was analyzed by flow
cytometry using FITC and DAPI channels, for un-cleaved
substrate and cleaved product respectively. Virus without Vpr-b-
lactamase was used for gating control. R5 inhibitor TAK-779
(1 mM) [58] was used to confirm R5-dependent entry.
RT assay
5610
5 mouse CD4
+ T cells were activated with anti-CD3/28 in
48-well-plates for 36 h. HIV-GFP (VSVG pseudotyped, MOI=2,
benzonase treated) was used for spin-infection. Cells were collected
at 0, 1, 2, 3, 6, 9, 12, 15 and 24 h post-infection, washed with PBS
and frozen at –80uC. As a control, AZT (15 mM) was added at
different time points and samples were collected starting from the
next time-point. Total DNA was extracted by DNeasy kit (Qiagen)
or phenol and dissolved in 50 ml AE buffer (Qiagen). Real-time
PCRs were done using primers and probes specific for U5, 2
nd
transfer and 2-LTR circles [59,60], Serial dilutions of HIV-GFP or
2-LTR plasmid in genomic DNA were used to generate a standard
curve in each plate. Calculation of cell number was determined
based on real-time PCR for gene encoding eukaryotic18S rRNA
(Hs99999901_s1, Taqman, Applied Biosystem) with common
sequence for human and mouse. Real-time PCRs were performed
using QuantiTect Multiplex PCR mix (Qiagen) in the i-Cycler
Sequence Detection System (Bio-Rad). The running conditions
and primer sequences were as the follows. For 2-LTR circles, 95uC
5 min, then 95uC4 5s ,5 5 uC 1 min, 72uC 1 min for 40 cycles. All
others, 95uC 5 min, then 95uC4 5s ,6 0 uC 1 min for 40 cycles.
Primer sequences for U5: Forward TCTCTGGTTAGACCA-
GATCTG, Reverse GTCTGAGGGATCTCTAGTTAC, probe
FAM-AGCCTCAATAAAGCT TGCCTTGAGTGC-TAMRA.
Primers for 2
nd strand transfer: Forward TTTTAGTCAGTGTG-
GAAAATCTGTAGC, reverse TACTCACCAGTCGCCGCC
probe: FAM-TCGACGCAGGACTCGGCTTGCT-TAMRA.
Primers for 2-LTR: Forward, TAGACCAGATCTGAGCC-
TGGGA, reverse, GTAGTTCTGC CAATCAGGGAAG, probe
FAM-AGCCTCAATAAAGCTTGCCTTGAGTGC-TAMRA.
To quantify copy numbers of integrated provirus, extracted DNAs
were subjected to a first-round PCR to amplify integrated HIV
signals using primers specific for HIV-1 and retrotransposon B2.
Primer sequences were: B2-1: TTCACAACTCTCGGT
GGATGGTGG; B2-2: GACCTTTGGAAGAGCAGTCG and
HIV-1 primers: NL750RC: TACTCACCAGTCGCCGCC;
NL800R: GAGCGTGGGTAGAGAGAGGAAG. Samples were
denatured at 95uC for 3 min, followed by 30 cycles at 95uCf o r4 5s ,
55uCf o r1m i n ,a n d7 2 uC for 3 min. Products generated from this
first round of amplification were diluted in water (1:1,200) and
subjected to real-time PCR using primers and probe specificfor HIV-
1U 5 .
Viral RNA analysis
Total RNA was purified using Qiagen RNeasy kit from cells
infected with HIV-GFP (VSVG) for 2 d. cDNAs were generated
from RNA by RNase H
2reverse transcriptase (Invitrogen) using
random primers. Real-time PCR was done using primers specific
for U5 and 18S rRNA. As control, no reverse transcriptase was
added at the time of cDNA preparation.
Gag protein analysis
Cells were infected with HIV-GFP (VSVG) in the presence or
absence of AZT (10 mM). One day post infection, cells were
treated with 0.01–0.04% pronase to remove the virus stuck to the
plasma membrane. Two days following infection, cell pellets and
supernatants were separated after centrifugation (2,000x g, 5 min)
and frozen at 280uC. Cells were lysed in RIPA buffer (10 mM
Tris, 150 mM NaCl, 0.1% SDS, 1% Triton, 1% Deoxycholate,
5 mM EDTA). p24 in cell lysates and supernatants was measured
by ELISA. ELISA was set up using primary and secondary p24
antibody purchased from CLINIQA. Recombinant HIV-1 p24
was included for standard curves. For western blots, aliquots of cell
lysates were separated on 12% acrylamide gradient gels and
transferred to PVDF membrane. Western blots were probed with
a monoclonal antibody to HIV-1 p24 (NIH AIDs Research and
Reference Reagent Program). Membranes were stripped and re-
probed with anti-tubulin (Sigma, antibody recognizes both human
and mouse tubulin) as loading control.
Infectivity assays
Infectious HIV-1 in supernatants was quantified by using the
Tzmbl cell line [38]. Briefly, Tzmbl cells (HeLa cells expressing
hCD4, CXCR4 and CCR5, NIH AIDS reagents) were seeded in
48-well plates and inoculated with HIV-1-containing supernatant,
which was serially diluted to make sure the infection was not
saturated. AZT and TAK-779 were added at 16 h post-infection
to prevent secondary infection. Thirty-six hours later, the cells
were lysed and firefly luciferase activity was determined (Promega).
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Human or mouse T cells were infected with HIV-GFP (VSVG)
at MOI of 2. For human cells, 3 d after infection, cells were
pelleted and fixed. For mouse T cells, cells were FACS sorted for
GFP
+ cells and allowed to recover overnight at 37uC. Cells were
resuspended in 1 ml of PBS, transferred to 1.5 ml Eppendorf tubes
and centrifuged at 8006g for 1 minute. Pellets were fixed in 2.5%
glutaraldehyde for 2 h at 4uC and post-fixed with 1% osmium
tetroxide for 1.5 h at room temperature, then processed in a
standard manner and embedded in Embed 812 (Electron
Microscopy Sciences, Hatfield, PA). Semi-thin sections were cut
at 1 mm and stained with 1% Toluidine Blue to evaluate the
quality of preservation. Ultrathin sections (60 nm) were cut,
mounted on formover coated copper grids and stained with uranyl
acetate and lead citrate by standard methods. Stained grids were
examined using a Philips CM-12 election microscope and
photographed with a Gatan (1k61k) digital camera.
Supporting Information
Figure S1 VSVG mediates efficient entry into mouse and
human T cells. Entry assay for VSVG-pseudotyped HIV-1
containing Vpr-b-lactamase at MOI of 0.04 was performed as
described in the legend to Figure 1.
Found at: doi:10.1371/journal.pone.0002035.s001 (0.90 MB EPS)
Figure S2 Benzonase treatment did not affect the infectivity of
HIV-1. Dilutions of the viruses before and after benzonase
treatment were added to Tzmbl reporter cells. Firefly luciferase
assays were done at 48 h post-infection.
Found at: doi:10.1371/journal.pone.0002035.s002 (0.64 MB EPS)
Figure S3 PI3K mediated pathways are important for HIV-1
infection in primary mouse T cells. CD4+ T cells from hCyclin T1
transgenic mice were activated with anti-CD3/28 and infected
with HIV-GFP (VSVG). PI3K inhibitors wortmannin and
Ly294002 were added at the time of infection at concentrations
indicated and removed at 24 h post infection. DMSO was used as
the control. Infection efficiency was assayed by FACS for GFP
expression at 48 h post infection.
Found at: doi:10.1371/journal.pone.0002035.s003 (0.66 MB EPS)
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